Journal: American Journal of Translational Research

Article Title: lncRNA PART1 mitigates MPP + -induced neuronal injury in SH-SY5Y cells via micRNA-106b-5p/MCL1 axis

doi:

Figure Lengend Snippet: The sequence of reagents used in cell transfection

Article Snippet: To examine whether microRNA-106b-5p targeted PART1 or MCL1 directly, PART1-WT, PART1-MUT, MCL1-WT and MCL1-MUT reporter vectors were purchased from Promega (Madison, WI, USA).

Techniques: Sequencing

Journal: American Journal of Translational Research

Article Title: lncRNA PART1 mitigates MPP + -induced neuronal injury in SH-SY5Y cells via micRNA-106b-5p/MCL1 axis

doi:

Figure Lengend Snippet: The sequence of primers

Article Snippet: To examine whether microRNA-106b-5p targeted PART1 or MCL1 directly, PART1-WT, PART1-MUT, MCL1-WT and MCL1-MUT reporter vectors were purchased from Promega (Madison, WI, USA).

Techniques: Sequencing

Journal: American Journal of Translational Research

Article Title: lncRNA PART1 mitigates MPP + -induced neuronal injury in SH-SY5Y cells via micRNA-106b-5p/MCL1 axis

doi:

Figure Lengend Snippet: The expression of PART1 in PD. A: The protein expressions of TH and α-synuclein were examined by western blot in the mouse model of PD. β-actin was used as lading control; B: The expression of PART1 in brain tissues was examined in the mouse model of PD by RT-qPCR; C: The expression of PART1 in SH-SY5Y cells treated with MPP+ was examined by RT-qPCR. **P<0.01. PD: Parkinson’s disease; MPP+: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Article Snippet: To examine whether microRNA-106b-5p targeted PART1 or MCL1 directly, PART1-WT, PART1-MUT, MCL1-WT and MCL1-MUT reporter vectors were purchased from Promega (Madison, WI, USA).

Techniques: Expressing, Western Blot, Quantitative RT-PCR

Journal: American Journal of Translational Research

Article Title: lncRNA PART1 mitigates MPP + -induced neuronal injury in SH-SY5Y cells via micRNA-106b-5p/MCL1 axis

doi:

Figure Lengend Snippet: Overexpression of PART1 alleviated neuronal injury. SH-SY5Y cells transfected with pcDNA3.1-NC or PART1 pcDNA3.1 were treated with 1 μM MPP+ for 48 h. A: The expression of PART1 was examined by RT-qPCR; B: The cell viability was assessed by CCK8 assay; C: The cell apoptosis rate was detected by Annexin V-FITC/PI assay; D: The expression of cleaved caspase 3 was detected by western blot; E: The activity of cleaved caspase 3 was detected; F-H: The levels of inflammatory cytokines were examined by ELISA; I-K: The levels of LDH, ROS and SOD were examined. *P<0.05, **P<0.01. MPP+: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; LDH: Lactate dehydrogenase; ROS: Reactive oxygen; SOD: Superoxide dismutase.

Article Snippet: To examine whether microRNA-106b-5p targeted PART1 or MCL1 directly, PART1-WT, PART1-MUT, MCL1-WT and MCL1-MUT reporter vectors were purchased from Promega (Madison, WI, USA).

Techniques: Over Expression, Transfection, Expressing, Quantitative RT-PCR, CCK-8 Assay, Western Blot, Activity Assay, Enzyme-linked Immunosorbent Assay

Journal: American Journal of Translational Research

Article Title: lncRNA PART1 mitigates MPP + -induced neuronal injury in SH-SY5Y cells via micRNA-106b-5p/MCL1 axis

doi:

Figure Lengend Snippet: PART1 targets microRNA-106b-5p directly. (A) The predictive binding site of PART1 was predicted by Starbase 2.0; (B) The expression of microRNA-106b-5p was examined by RT-qPCR in SH-SY5Y cells transfected with PART1 pcDNA3.1; (C) The expression of microRNA-106b-5p was examined by RT-qPCR in the SH-SY5Y cells transfected with mimics NC and microRNA-106b-5p mimics; (D) The DLR assay was used to detect the binding relationship between microRNA-106b-5p and PART1 in SH-SY5Y cells co-transfected with PART1-WT or PART1-MUT and mimics NC or microRNA-106b-5p mimics; (E, F) The RIP assay (E) and RNA pull down assay (F) were used to examine the interaction between PART1 and microRNA-106b-5p in SH-SY5Y cells; (G, H) The expressions of microRNA-106b-5p in SH-SY5Y cells (G) and PD mouse model (H) were examined by RT-qPCR; (I) The correlation analysis of PART1 and microRNA-106b-5p in PD mouse model. **P<0.01. DLR: Dual-luciferase report; PD: Parkinson’s disease.

Article Snippet: To examine whether microRNA-106b-5p targeted PART1 or MCL1 directly, PART1-WT, PART1-MUT, MCL1-WT and MCL1-MUT reporter vectors were purchased from Promega (Madison, WI, USA).

Techniques: Binding Assay, Expressing, Quantitative RT-PCR, Transfection, Pull Down Assay, Luciferase

Journal: American Journal of Translational Research

Article Title: lncRNA PART1 mitigates MPP + -induced neuronal injury in SH-SY5Y cells via micRNA-106b-5p/MCL1 axis

doi:

Figure Lengend Snippet: PART1 attenuated the injury of SH-SY5Y cells induced by MPP+ via microRNA-106b-5p/MCL1 axis. After transfection with PART1 pcDNA3.1, microRNA-106b-5p mimics, and MCL1 siRNA, SH-SY5Y cells were treated with 1 μM MPP+ for 48 h. A: The expression of MCL1 was examined by western blot; B: The cell viability was assessed by CCK8 assay; C: The cell apoptosis rate was detected by Annexin V-FITC/PI assay; D: The expression of cleaved caspase 3 was detected by western blot; E: The activity of cleaved caspase 3 was detected; F-H: The levels of inflammatory cytokines were examined by ELISA; I-K: The levels of LDH, ROS and SOD were examined. *P<0.05, **P<0.01. MPP+: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Article Snippet: To examine whether microRNA-106b-5p targeted PART1 or MCL1 directly, PART1-WT, PART1-MUT, MCL1-WT and MCL1-MUT reporter vectors were purchased from Promega (Madison, WI, USA).

Techniques: Transfection, Expressing, Western Blot, CCK-8 Assay, Activity Assay, Enzyme-linked Immunosorbent Assay

Journal: American Journal of Translational Research

Article Title: lncRNA PART1 mitigates MPP + -induced neuronal injury in SH-SY5Y cells via micRNA-106b-5p/MCL1 axis

doi:

Figure Lengend Snippet: The schematic diagram of PART1/microRNA-106b-5p/MCL1 axis.

Article Snippet: To examine whether microRNA-106b-5p targeted PART1 or MCL1 directly, PART1-WT, PART1-MUT, MCL1-WT and MCL1-MUT reporter vectors were purchased from Promega (Madison, WI, USA).

Techniques: